TcB pAb remedies were designed according to pet weights and established titers [14] previously. Clinical examinations were performed in days 0, 1, 3, 5, 7,
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor
mTORC1 inhibitor
TcB pAb remedies were designed according to pet weights and established titers [14] previously. Clinical examinations were performed in days 0, 1, 3, 5, 7,